Veru has completed enrollment for the second portion of a Phase 1/2 study of VERU-111, its investigational therapy for men with metastatic castration-resistant prostate cancer (mCRPC) who failed to respond to treatment with a new androgen receptor inhibitor. The open-label Phase 1/2 trial (NCT03752099) will evaluate the compound’s safety and efficacy in 40 men with mCRPC at 13 clinical sites across the U.S., including multiple centers in Texas and Maryland. All study participants have mCRPC…
You must be logged in to read/download the full post.
The post Veru Completes Enrollment for Second Part of Phase 1/2 VERU-111 Trial appeared first on BioNewsFeeds.